Edition:
United States

Achillion Pharmaceuticals Inc (ACHN.OQ)

ACHN.OQ on NASDAQ Stock Exchange Global Select Market

4.15USD
20 Oct 2017
Change (% chg)

$-0.01 (-0.24%)
Prev Close
$4.16
Open
$4.20
Day's High
$4.25
Day's Low
$4.03
Volume
408,925
Avg. Vol
404,679
52-wk High
$7.07
52-wk Low
$3.15

Latest Key Developments (Source: Significant Developments)

RTW Investments reports 5.2 pct passive stake in Achillion Pharmaceuticals - SEC filing‍​
Thursday, 28 Sep 2017 03:09pm EDT 

Sept 28 (Reuters) - RTW Investments LP::RTW Investments LP reports 5.2 percent passive stake in Achillion Pharmaceuticals Inc as of September 18, 2017 - SEC filing‍​.  Full Article

Achillion Pharmaceuticals says Joel Barrish plans to leave co
Monday, 10 Jul 2017 04:05pm EDT 

July 10 (Reuters) - Achillion Pharmaceuticals Inc :Achillion Pharmaceuticals Inc - ‍announced that Joel Barrish, executive vice president and chief scientific officer, plans to leave company.Achillion Pharmaceuticals Inc - Achillion continues to dose PNH patients in a phase 2 study of its first complement factor D inhibitor, ACH-4471​.Achillion Pharmaceuticals Inc - ‍ACH-4471 is also poised to begin a phase 2 clinical study in C3G​.  Full Article

Achillion Q1 loss per share $0.15
Thursday, 4 May 2017 06:05am EDT 

May 4 (Reuters) - Achillion Pharmaceuticals Inc ::Achillion reports first quarter 2017 financial results and provides update on clinical programs.Q1 loss per share $0.15.Q1 earnings per share view $-0.12 -- Thomson Reuters I/B/E/S.  Full Article

Achillion announces initiation of patient dosing in phase 2 study of ACH-4471
Thursday, 6 Apr 2017 06:05am EDT 

Achillion Pharmaceuticals Inc : Achillion announces initiation of patient dosing in phase 2 study of ACH-4471 for paroxysmal nocturnal hemoglobinuria . Achillion Pharmaceuticals Inc - interim results from phase 2 open-label study of ACH-4471 are anticipated during q2 of 2017 .Achillion - look forward to evaluating ACH-4471 in phase 2 trial for patients with C3 glomerulopathy that co plans initiate during H2 of this year.  Full Article

Achillion Pharmaceuticals Inc says files for mixed shelf of upto $250 million
Thursday, 23 Feb 2017 05:26pm EST 

Achillion Pharmaceuticals Inc :Achillion Pharmaceuticals Inc says files for mixed shelf of upto $250 million - SEC filing.  Full Article

Achillion Pharmaceuticals Q4 revenue $15 million
Thursday, 23 Feb 2017 04:05pm EST 

Achillion Pharmaceuticals Inc : Achillion reports 2016 fourth quarter and year-end financial results . Sees FY 2017 loss per share $0.70 to $0.75 . Q4 revenue $15 million . Q4 revenue view $0 -- Thomson Reuters I/B/E/S . Expects that research and development expenses during 2017 will be approximately $75 - 80 million . Net cash used in operating activities in 2017 will be approximately $70 - 75 million .FY2017 earnings per share view $-0.40 -- Thomson Reuters I/B/E/S.  Full Article

Achillion Pharmaceuticals reports Q2 loss per share $0.14
Thursday, 4 Aug 2016 04:05pm EDT 

Achillion Pharmaceuticals Inc : Achillion reports second quarter 2016 financial results .Achillion Pharmaceuticals Inc qtrly loss per share $0.14.  Full Article

Achillion presents interim phase 1 results for ACH-4471
Friday, 10 Jun 2016 03:30am EDT 

Achillion says : Presents interim phase 1 results for ACH-4471, a novel orally-administered factor D inhibitor . Results indicate up to 100% inhibition of alternative-pathway activity in hemolysis and Wieslab assays after oral dosing of ACH-447 .Results support initiation of phase 1 trial during q2 and phase 2 studies for PNH and C3G by year-end 2016.  Full Article

Achillion Pharmaceuticals Inc reaffirms FY 2015 revenue guidance; raises FY 2015 EPS guidance
Thursday, 5 Nov 2015 04:05pm EST 

Achillion Pharmaceuticals Inc:Expects FY 2015 total annual revenue to be $66 million, representing the total premium paid by JJDC associated with its equity purchase of Achillion common stock.Expects FY 2015 net loss per share to be approximately $0.08 - 0.10 per share.FY 2015 EPS of $(0.28) - Thomson Reuters I/B/E/S.  Full Article

BRIEF-RTW Investments reports 5.2 pct passive stake in Achillion Pharmaceuticals - SEC filing‍​

* RTW Investments LP reports 5.2 percent passive stake in Achillion Pharmaceuticals Inc as of September 18, 2017 - SEC filing‍​ Source text: (http://bit.ly/2wXrbF8) Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)